ProBioGen AG Signs Next GlymaxX® ADCC Technology Deal With TOP 10 Pharma Company for Therapeutic Antibody Platform
2/20/2013 11:47:45 AM
More...
|
ProBioGen AG Launches Unique Portfolio of Engineered High-Performance Cell Lines for Biopharmaceutical Manufacturing
11/12/2012 1:01:56 PM
More...
|
ProBioGen AG Introduces Novel Productivity-Boosting Technology for Therapeutic Protein Production: "Pathway Modulator"
6/14/2012 9:21:39 AM
More...
|
Ceva Takes Commercial License for ProBioGen AG's AGE1.CR® Cell Line for Viral Vaccine Production
3/15/2012 9:50:23 AM
More...
|
ProBioGen AG and Inhibrx Sign License Deal on GlymaxX(R) ADCC Technology for Therapeutic Antibodies Development
10/25/2011 9:56:27 AM
More...
|
Boehringer Ingelheim Corporation Licenses ProBioGen AG's Novel GlymaxX(R) Technology
8/10/2011 10:46:15 AM
More...
|
Life Technologies (LIFE) and ProBioGen AG Announce Freedom(TM) Cell Line Development Royalty-Free Kits to Advance Early Stage Biologic Drug Production
5/17/2011 9:30:15 AM
More...
|
ProBioGen AG Presents GlymaxX - The Novel Glyco-Engineering Technology
11/11/2010 12:49:34 PM
More...
|
Minapharm Acquires Majority Stake in ProBioGen AG; Dr. Wieland Wolf Appointed New CEO
6/16/2010 6:35:08 AM
More...
|
Sanofi Pasteur (SASY.PA) Accesses ProBioGen AG's AGE1.CR® Cell Lines for Various Pox-vectored Vaccine Products Under Development
2/5/2009 10:28:42 AM
More...
|
|